Navigation Links
When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
Date:9/22/2007

at cover the surface of the proteins: When two proteins react they squeeze the water molecules out of the area where they bind together. This displacement changes the density of the liquid slightly which, in turn, alters its index of refraction.

BSI has some potential cost advantages compared to current techniques. The price of the equipment required for BSI is modest and the entire system could easily be miniaturized and integrated with lab on a chip systems, says Bornhop. It is also easy to adapt for high-throughput operation: processing hundreds or thousands of different samples at the same time, he says.

Vanderbilt has applied for and received two patents on the process and has several other patents pending. The university has issued an exclusive license to develop the technology to Molecular Sensing, Inc. Bornhop is one of the founders of the start-up and serves as its chief scientist. The company plans on completing a prototype system this fall.


'/>"/>

Contact: David F. Salisbury
david.salisbury@vanderbilt.edu
615-343-6803
Vanderbilt University
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology technology :

1. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
2. Continuous-Elution Electrophoresis for Purification of the Baculovirus-Expressed Coronavirus Structural Proteins, Rev A
3. Application of the Bio-Plex Cell Lysis Kit in Western Blot Analysis of Phosphoproteins, Rev A
4. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
5. Simple, Sensitive Isotyping of Mouse Monoclonal Antibodies
6. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
7. Mirus announces new method for making antibodies
8. Using THERMAL DESORPTION GAS CHROMATOGRAPHY for the identification of fragrance and other components in cosmetic products
9. Milwaukee takes another step in electronic patient data exchange
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Early Stage: Step 11 - Other forms of finance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...v. 23, 2009 In a provocative new study, a Univers...oxide emissions the major cause of global warming...collapses or society builds the equivalent of one ...nlikely that there will be any substantial near-te...n carbon dioxide emission rates," says the new pap...
(Date:11/23/2009)...N,Nov.23/PRNewswire-FirstCall/-YMBioSciencesInc.(N...entcompanythatidentifiesandadvancesadiverseportfol...ofdevelopment,todayreportedthatCytopia(ASX:CYT)has...87,apotent,orally-administeredJAK1/JAK2inhibitor.T...nesota.AproposaltomergeCytopiaintoYMhasbeenpreviou...
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire/--Frost&Sullivan,theG...fordemonstratingleadershipandinnovationThursday,No...AwardsBanquetheldinSanAntonio,Texas. ,, (Logo: ...O ) ,, TheHealthcareInnovationAwardsaregiventoc...eliveryandmanagementofhealthcare.Suchcompanieshave...
(Date:11/20/2009)... Nov. 20 Veridiam (www.veridiam.co...ze company category at the 2009 Workplace Excellen...go Society for Human Resources Management and reco...ractices. ,, Veridiam was one of nine winners, ...panies, honored at the recent awards ceremony. San...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2
...PRNewswire-FirstCall/ - Victhom Human Bionics Inc....ing of its updated corporate Website at www.victh... highlights advances in the Company,s two operatin...mplantable neurostimulation device for gait disord...cturing computerized prostheses for above-knee amp...
..., Jan. 9 Schering-Plough Corporation (NYSE: SGP...tion by Thomas P. Koestler, Ph.D., executive vice ...Institute, at the 27th Annual J.P. Morgan Healthca... at approximately 3:30 p.m. (PST) (6:30 p.m. EST).... R&D pipeline and select projects in developme...
... TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Jan....oday that GSK has resubmitted the New Drug Applica...n (FDA) requesting approval of Solzira (TM) (gaba...he treatment of moderate-to-severe primary Restles...d that the data in a single study be reformatted. ...
Other Biology Technology:Victhom Announces Launch of Enhanced Company Website 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlif...ort revealing that the last remaining population o...y due to the rising tide of poaching and habitat l... inform Russian officials of what needs to be done...iggest cat. , The report was releas...
(Date:11/24/2009)..., Md. (November 24, 2009) New research on bacteri...cosystems reveals predictable temporal patterns, s...ies as markers for monitoring climate change in th... the Proceedings of the National Academy of Scien...es in the six rivers shifted synchronously over ti...
(Date:11/23/2009)...n, D.C. The community-associated strain of the de...sistant to most common antibioticsposes a far grea...ing its way into hospitals, according to a study i...ses . , The new threat is easily picked up in f...nd has increased the overall burden of MRSA within...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Reward Yourself by Taking Your Dog to Obedience Training 58083 1Reward Yourself by Taking Your Dog to Obedience Training 58083 2Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 1Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 2Catholics to Rally at USCCB Headquarters in Washington DC Re 3A Healthcare Our Bishops and Abortion 58079 1Catholics to Rally at USCCB Headquarters in Washington DC Re 3A Healthcare Our Bishops and Abortion 58079 2
...HOUSTON -- (Nov. 19, 2008) -- Rice University scie...e stubborn pollutant TCE have created a method tha...ace of a catalyst as individual chemical bonds are...of the bonds between the atoms of our molecules," ... these vibrations change frequency and intensity w...
...MADISON, WI, NOVEMBER 17, 2008 Global land use pat...demand creative urban stormwater management. Tradi... the flow of runoff to waterways, but generally do...d by extensive pavement and compacted urban soils ...portunities affects groundwater recharge and has n...
...BOZEMAN -- The U.S. Department of Energy on Monday...stration Partnership at Montana State University t...f carbon dioxide into the sandstone rock layer ben...third and final phase of federal funding for the B...mately $14 million of the federal money will stay ...
Other Biology News:Researchers shed new light on catalyzed reactions 2Researchers shed new light on catalyzed reactions 3Urban trees enhance water infiltration 2Montana State partnership receives $66.9M for carbon sequestration 2Montana State partnership receives $66.9M for carbon sequestration 3
Acrylamide from GE Healthcare, formerly Amersham Biosciences
Assay Diluent Trial Pack from BioFX Laboratories, Inc.
...lone/PAD: ZMD.474. Immunogen: Synthetic peptide d...ophilin-3. Specificity: Specific for the internal...y: Mouse (positive controls: mouse brain homogenat...pplications: Western blotting Immunohistochemistry...
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
Biology Products: